Searching map area
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia
? TBD
scientific article
Join to rate
Ratings
0
Nobody has rated this yet. Be the first!
Lists
0
Join to rate
Originalonlinelibrary.wiley.com
Instance of
Scholarly article
Author
Martha Wadleigh
Suzanne Kamel-Reid
Peter D. Emanuel
Brian Druker
Richard A. Larson
Martin S. Tallman
Elisabeth Paietta
Frederick R. Appelbaum
Peter D. Emanuel
Richard A. Larson
Brian Druker
Subject
phase II clinical trial
Leukemia
Imatinib
Imatinib
ABL1 BCR::ABL
Wikidata